Non-interventional Study With NOVOCART® 3D for the Treatment of Cartilage Defects of the Knee in Pediatric Patients
Launched by TETEC AG · Dec 2, 2019
Trial Information
Current as of April 30, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment called NOVOCART® 3D for young patients with cartilage defects in their knees. Cartilage is a smooth tissue that helps joints move easily, and problems with it can cause pain and limit movement. This trial aims to find out how well NOVOCART 3D works, how safe it is, and how it affects healthcare costs for children and teenagers aged 13 to 17 who have closed growth plates, which means their bones are no longer growing.
If a young person is between 13 and 17 years old and has a medical reason to use NOVOCART 3D, they might be eligible to participate in this study. There are no specific exclusions, meaning many young patients could potentially join. Those who participate can expect to receive the NOVOCART 3D treatment and be monitored for its effectiveness and safety. It's important to note that this study is currently active but not recruiting new participants, so no new patients will be added at this time.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 13 - 17 years old
- • Medicinal indication for NOVOCART 3D treatment
- Exclusion criteria:
- • • none
About Tetec Ag
Tetec AG is a pioneering biotechnology company focused on the development and commercialization of innovative therapies for the treatment of severe diseases, particularly in the fields of regenerative medicine and immunotherapy. With a commitment to advancing healthcare solutions, Tetec AG leverages cutting-edge technologies and a robust scientific foundation to create novel products that enhance patient outcomes. The company is dedicated to conducting rigorous clinical trials, ensuring compliance with international regulatory standards, and fostering collaborations with leading research institutions to drive its mission forward.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
München, Bayern, Germany
Mannheim, Baden Württemberg, Germany
Stuttgart, Baden Württemberg, Germany
München, Bayern, Germany
Regensburg, Bayern, Germany
Kiel, Schleswig Holstein, Germany
Patients applied
Trial Officials
Peter Angele, Prof. MD
Principal Investigator
Universitätsklinikum Regensburg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials